Upstream Bio's Verekitug Shows Significant Efficacy in Phase 2 Severe Asthma Trial
核心洞察
Verekitug demonstrated statistically significant reductions in annualized asthma exacerbation rates of 56% and 39% with two different dosing regimens compared to placebo in the Phase 2 VALIANT trial.
The TSLP receptor (搜索) antagonist also showed clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide levels across both dose groups in 478 severe asthma (搜索) patients.
Over 90% of eligible patients transitioned to the long-term extension study, with Upstream Bio (搜索) planning to advance verekitug into Phase 3 trials following regulatory discussions.
Upstream Bio (搜索) announced positive top-line results from its Phase 2 VALIANT clinical trial, demonstrating that verekitug, the only known clinical-stage antagonist targeting the thymic stromal lymphopoietin (搜索) (TSLP) receptor, achieved statistically significant and clinically meaningful reductions in severe asthma (搜索) exacerbations. The 478-patient global study met its primary endpoint with impressive efficacy across multiple measures.
Primary Endpoint Success with Dual Dosing Regimens
The VALIANT trial met its primary endpoint of reducing the annualized asthma exacerbation rate (AAER) with both dosing schedules tested. Verekitug demonstrated a 56% reduction in AAER (p<0.0003) when administered at 100 mg every 12 weeks and a 39% reduction (p<0.02) when given at 400 mg every 24 weeks, compared to placebo.
"We are excited to share these robust data from VALIANT, which indicate the potential of verekitug's meaningful clinical effect in severe asthma (搜索) and provide a strong foundation as we advance verekitug into Phase 3 clinical trials as quickly as possible," said Aaron Deykin, MD, Chief Medical Officer and Head of Research & Development at Upstream Bio (搜索).
Significant Improvements in Lung Function and Inflammation
Beyond exacerbation reduction, verekitug delivered substantial improvements in secondary endpoints. Placebo-adjusted improvement in forced expiratory volume in one second (FEV1) reached 122 mL at week 60 with the 100 mg q12w regimen and 139 mL with the 400 mg q24w dosing.
The drug also demonstrated potent anti-inflammatory effects, suppressing exhaled nitric oxide (FeNO) by 20.4 ppb (p<0.0003) in the 100 mg q12w group and by 26.3 ppb (p<0.0001) in the 400 mg q24w group at week 60. These reductions represented mean decreases from baseline of 43.5% (p=0.03) and 44.9% (p=0.03), respectively.
Additional pre-specified analyses at week 24 revealed statistically significant placebo-adjusted improvements in both FEV1 and FeNO with both effective dose regimens.
Favorable Safety Profile and High Patient Retention
Verekitug was generally well tolerated across all active doses, demonstrating a safety profile consistent with previous studies. The strong tolerability profile contributed to exceptional patient retention, with over 90% of eligible patients rolling over to the Phase 2 VALOUR long-term extension study.
Unique Mechanism Targeting Upstream Inflammation
Verekitug represents a novel approach as a recombinant fully human IgG1 monoclonal antibody that binds to the TSLP receptor (搜索) and inhibits proinflammatory signaling. TSLP is a cytokine positioned upstream in the inflammatory cascade, where its activation initiates downstream targets including IL-4 (搜索), IL-5 (搜索), IL-13 (搜索), IL-17 (搜索) and IgE.
"Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor (搜索) presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases," according to the company's description of the mechanism.
Addressing Substantial Unmet Medical Need
Severe asthma (搜索) affects approximately 350 million people worldwide, with five to 10 percent suffering from the severe form of the disease. In the United States, approximately 1.3 million patients are eligible for biologic therapies, though utilization remains limited relative to the eligible population size.
"Severe asthma (搜索), when unable to be controlled by standard of care measures, can significantly and chronically disrupt patients' quality of life, and put them at risk for potentially life-threatening exacerbation events that can lead to emergency rooms visits and hospitalizations," said Michael Wechsler, MD, MMSc, Professor of Medicine and Director of National Jewish Cohen Family Asthma Institute.
Phase 3 Development Plans
The VALIANT trial was designed with endpoints that could potentially support regulatory submissions for product approval, pending interactions with regulatory authorities. Upstream Bio (搜索) has commenced planning activities for Phase 3 trials in both severe asthma (搜索) and chronic rhinosinusitis with nasal polyps (搜索) (CRSwNP), intending to initiate registrational trials in both indications following planned regulatory discussions.
"We intend to rapidly advance verekitug into Phase 3 trials in severe asthma (搜索) and CRSwNP," stated Rand Sutherland, MD, Chief Executive Officer of Upstream Bio (搜索). "As we transition into a late clinical-stage company pursuing substantial market opportunities, our focus remains on disciplined execution and expanding Upstream Bio's capabilities to support long-term growth."
Comprehensive Clinical Development Program
The VALIANT success builds on positive results from the VIBRANT trial in CRSwNP patients. Verekitug is also being evaluated in the ongoing Phase 2 VENTURE trial for moderate-to-severe chronic obstructive pulmonary disease (搜索) (COPD), where enrollment has exceeded 60% of the target population.
The comprehensive clinical program positions verekitug as a potential treatment across multiple respiratory inflammatory conditions, leveraging its unique mechanism of targeting the TSLP receptor (搜索) upstream in the inflammatory cascade.